Beam Therapeutics (BEAM) Financials

$28.90 -1.18 (-3.92%)

Closing price 04:00 PM Eastern

Extended Trading

$29.21 +0.31 (+1.07%)

As of 07:56 PM Eastern

Annual Income Statements for Beam Therapeutics

This table shows Beam Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-91	-196	-371	-289	-133	-377	-80
Consolidated Net Income / (Loss)	-78	-195	-371	-289	-133	-377	-80
Net Income / (Loss) Continuing Operations	-78	-195	-371	-289	-133	-377	-80
Total Pre-Tax Income	-78	-195	-371	-260	-131	-377	-80
Total Operating Income	-75	-133	-392	-338	-176	-416	-384
Total Gross Profit	0.02	0.02	52	61	378	64	140
Total Revenue	0.02	0.02	52	61	378	64	140
Operating Revenue	0.02	0.02	52	61	378	64	140
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	75	133	444	399	554	479	523
Selling, General & Admin Expense	21	30	57	88	117	112	114
Research & Development Expense	55	103	387	312	437	368	410
Total Other Income / (Expense), net	-3.17	-62	22	78	45	39	304
Interest Expense	-2.23	-1.05	0.01	-15	-47	-49	-44
Interest & Investment Income	-	-	-	-	-	-	255
Other Income / (Expense), net	-5.40	-63	22	63	-1.35	-10	4.82
Income Tax Expense	-	0.00	0.00	3.41	1.37	0.04	0.00
Basic Earnings per Share	($14.05)	($4.19)	($5.77)	($4.13)	($1.72)	($4.58)	($0.81)
Weighted Average Basic Shares Outstanding	6.48M	46.73M	64.23M	70.02M	77.15M	82.31M	98.91M
Diluted Earnings per Share	($14.05)	($4.19)	($5.77)	($4.13)	($1.72)	($4.58)	($0.81)
Weighted Average Diluted Shares Outstanding	6.48M	46.73M	64.23M	70.02M	77.15M	82.31M	98.91M
Weighted Average Basic & Diluted Shares Outstanding	6.48M	46.73M	68.73M	72.40M	81.66M	83.69M	101.86M

This table shows Beam Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-83	-96	143	-99	-91	-97	-90	-109	-102	-113	244
Consolidated Net Income / (Loss)	-83	-96	143	-99	-91	-97	-90	-109	-102	-113	244
Net Income / (Loss) Continuing Operations	-83	-96	143	-99	-91	-97	-90	-109	-102	-113	244
Total Pre-Tax Income	-83	-96	48	-99	-91	-97	-189	-109	-102	-113	244
Total Operating Income	-102	-108	133	-104	-105	-107	-100	-119	-120	-127	-17
Total Gross Profit	20	17	316	7.41	12	14	30	7.47	8.47	9.70	114
Total Revenue	20	17	316	7.41	12	14	30	7.47	8.47	9.70	114
Operating Revenue	20	17	316	7.41	12	14	30	7.47	8.47	9.70	114
Total Operating Expenses	122	125	183	112	117	121	130	127	129	137	131
Selling, General & Admin Expense	25	25	43	27	30	27	29	28	27	27	32
Research & Development Expense	98	100	140	85	87	94	101	99	102	110	99
Total Other Income / (Expense), net	19	12	11	5.46	14	9.84	9.68	10	18	14	262
Interest Expense	-12	-13	-12	-12	-14	-12	-11	-9.86	-12	-11	-11
Other Income / (Expense), net	7.42	-0.52	-0.76	-6.39	-0.31	-2.26	-1.25	0.18	5.56	3.18	-4.10
Basic Earnings per Share	($1.08)	($1.22)	$1.91	($1.21)	($1.11)	($1.17)	($1.09)	($1.24)	($1.00)	($1.10)	$2.53
Weighted Average Basic Shares Outstanding	76.34M	79.02M	77.15M	81.70M	82.31M	82.41M	82.31M	87.98M	102.00M	102.57M	98.91M
Diluted Earnings per Share	($1.08)	($1.22)	$1.91	($1.21)	($1.11)	($1.17)	($1.09)	($1.24)	($1.00)	($1.10)	$2.53
Weighted Average Diluted Shares Outstanding	76.34M	79.02M	77.15M	81.70M	82.31M	82.41M	82.31M	87.98M	102.00M	102.57M	98.91M
Weighted Average Basic & Diluted Shares Outstanding	79.20M	81.50M	81.66M	82.31M	82.42M	82.81M	83.69M	100.56M	101.16M	101.47M	101.86M

This table details how cash moves in and out of Beam Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-97	126	396	-327	199	-155	12
Net Cash From Operating Activities	-72	-96	-66	23	-149	-347	-345
Net Cash From Continuing Operating Activities	-72	-96	-66	23	-149	-347	-345
Net Income / (Loss) Continuing Operations	-78	-195	-371	-289	-133	-377	-80
Consolidated Net Income / (Loss)	-78	-195	-371	-289	-133	-377	-80
Depreciation Expense	3.50	4.74	7.45	14	20	22	22
Amortization Expense	-0.92	0.12	-0.08	-0.98	-30	-23	-16
Non-Cash Adjustments To Reconcile Net Income	12	92	-109	378	109	129	-140
Changes in Operating Assets and Liabilities, net	-8.17	2.20	406	-80	-116	-99	-131
Net Cash From Investing Activities	-67	-100	-294	-461	72	185	-121
Net Cash From Continuing Investing Activities	-66	-99	-294	-461	72	185	-121
Purchase of Property, Plant & Equipment	-13	-16	-47	-49	-34	-8.95	-15
Acquisitions	-	-	-	-	0.00	0.00	-0.08
Purchase of Investments	-130	-282	-777	-1,617	-984	-486	-1,210
Divestitures	0.00	0.00	0.62	0.00	0.00	0.00	255
Sale and/or Maturity of Investments	76	199	529	1,205	1,090	680	848
Net Cash From Financing Activities	41	322	756	112	276	7.74	478
Net Cash From Continuing Financing Activities	41	322	756	112	276	7.74	478
Repayment of Debt	-0.46	-1.57	-	-2.29	-2.25	-0.49	0.00
Repurchase of Common Equity	-2.52	-2.06	-8.82	-0.19	0.00	0.00	0.00
Issuance of Common Equity	0.00	320	757	111	273	2.62	473
Other Financing Activities, net	0.19	3.16	7.51	2.73	6.13	5.60	4.77
Cash Interest Paid	0.19	0.56	0.57	0.38	0.16	0.03	0.00

This table details how cash moves in and out of Beam Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Change in Cash & Equivalents	-19	-63	267	-150	4.62	-62	53	244	-246	-14	27
Net Cash From Operating Activities	-85	-90	135	-100	-83	-88	-76	-104	-76	-81	-83
Net Cash From Continuing Operating Activities	-85	-90	135	-100	-83	-88	-76	-104	-76	-81	-83
Net Income / (Loss) Continuing Operations	-83	-96	143	-99	-91	-97	-90	-109	-102	-113	244
Consolidated Net Income / (Loss)	-83	-96	143	-99	-91	-97	-90	-109	-102	-113	244
Depreciation Expense	4.82	5.19	5.36	5.43	5.58	5.48	5.44	5.53	5.54	5.56	5.67
Amortization Expense	-7.57	-7.88	2.17	-6.58	-5.93	-5.62	5.03	-3.85	-4.62	-4.23	-3.26
Non-Cash Adjustments To Reconcile Net Income	26	35	7.81	35	33	31	21	29	15	45	-229
Changes in Operating Assets and Liabilities, net	-25	-26	-23	-35	-25	-22	-17	-25	10	-15	-101
Net Cash From Investing Activities	-41	-10	98	-53	87	25	126	-125	-170	66	108
Net Cash From Continuing Investing Activities	-41	-10	98	-53	87	25	126	-125	-170	66	108
Purchase of Property, Plant & Equipment	-16	-7.95	-3.59	-2.44	-1.96	-1.58	-2.97	-3.07	-3.14	-5.01	-3.73
Purchase of Investments	-391	-274	-53	-195	-134	-157	-	-339	-334	-176	-361
Sale and/or Maturity of Investments	366	271	155	144	224	183	129	217	167	246	218
Net Cash From Financing Activities	108	37	34	2.90	0.13	1.26	3.44	473	1.11	1.68	1.89
Net Cash From Continuing Financing Activities	108	37	34	2.90	0.13	1.26	3.44	473	1.11	1.68	1.89
Other Financing Activities, net	0.70	1.29	0.75	1.68	0.24	0.24	3.45	0.72	1.76	0.41	1.89

This table presents Beam Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	156	452	1,474	1,342	1,460	1,104	1,481
Total Current Assets	95	308	1,273	1,093	1,211	878	1,269
Cash & Equivalents	37	162	560	233	436	282	295
Short-Term Investments	55	138	406	845	754	569	950
Prepaid Expenses	2.70	8.65	7.36	15	21	27	23
Plant, Property, & Equipment, net	24	39	84	116	125	111	105
Total Noncurrent Assets	37	105	117	133	124	114	108
Other Noncurrent Operating Assets	37	105	117	133	124	114	108
Total Liabilities & Shareholders' Equity	156	452	1,474	1,342	1,460	1,104	1,481
Total Liabilities	55	206	648	608	478	370	243
Total Current Liabilities	29	102	213	224	206	182	97
Short-Term Debt	-	-	-	-	-	0.00	2.71
Accounts Payable	7.85	6.31	7.47	9.03	1.62	3.87	10
Accrued Expenses	7.85	18	68	50	112	47	55
Current Deferred Revenue	-	0.02	86	136	69	109	6.66
Other Current Liabilities	13	78	52	29	24	22	22
Total Noncurrent Liabilities	26	104	434	385	273	188	146
Noncurrent Deferred Revenue	-	0.39	262	202	110	33	0.00
Other Noncurrent Operating Liabilities	22	103	172	182	163	155	146
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-201	246	827	733	981	734	1,238
Total Preferred & Common Equity	-201	246	827	733	981	734	1,238
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-201	246	827	733	981	734	1,238
Common Stock	1.92	643	1,595	1,793	2,171	2,299	2,878
Retained Earnings	-203	-398	-768	-1,057	-1,190	-1,567	-1,641
Accumulated Other Comprehensive Income / (Loss)	0.02	-0.01	-0.05	-2.43	0.60	0.68	1.11

This table presents Beam Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025
Total Assets	1,350	1,332	1,354	1,291	1,360	1,261	1,171	1,467	1,391	1,311
Total Current Assets	1,109	1,083	1,095	1,040	1,122	1,029	946	1,248	1,175	1,099
Cash & Equivalents	157	250	226	169	288	293	230	528	282	268
Short-Term Investments	938	810	847	846	807	715	696	692	868	807
Prepaid Expenses	14	24	22	24	27	21	20	28	25	24
Plant, Property, & Equipment, net	111	122	128	128	121	117	114	110	109	108
Total Noncurrent Assets	130	127	131	123	117	114	112	110	107	104
Other Noncurrent Operating Assets	130	127	131	123	117	114	112	110	107	104
Total Liabilities & Shareholders' Equity	1,350	1,332	1,354	1,291	1,360	1,261	1,171	1,467	1,391	1,311
Total Liabilities	636	571	542	512	446	407	380	344	344	345
Total Current Liabilities	239	220	210	220	187	177	166	142	174	183
Short-Term Debt	-	-	-	-	-	-	-	-	-	1.19
Accounts Payable	7.02	14	6.89	3.18	2.79	4.43	3.81	7.70	11	9.55
Accrued Expenses	39	38	38	42	86	67	52	30	41	42
Current Deferred Revenue	160	143	139	153	72	85	89	85	106	110
Other Current Liabilities	33	25	26	22	26	21	21	18	17	19
Total Noncurrent Liabilities	397	351	333	291	259	230	214	202	170	163
Noncurrent Deferred Revenue	198	172	156	125	100	75	58	49	20	10
Other Noncurrent Operating Liabilities	199	179	177	167	160	154	156	153	150	152
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	714	762	812	779	913	854	791	1,123	1,047	966
Total Preferred & Common Equity	714	762	812	779	913	854	791	1,123	1,047	966
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	714	762	812	779	913	854	791	1,123	1,047	966
Common Stock	1,738	1,916	2,050	2,114	2,203	2,235	2,266	2,799	2,825	2,856
Retained Earnings	-1,019	-1,154	-1,237	-1,333	-1,289	-1,380	-1,476	-1,676	-1,778	-1,891
Accumulated Other Comprehensive Income / (Loss)	-4.67	-0.77	-2.02	-2.02	-0.92	-1.11	1.76	0.16	0.01	0.79

This table displays calculated financial ratios and metrics derived from Beam Therapeutics' official financial filings.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	33.33%	215,916.67%	17.51%	520.01%	-83.18%	120.01%
EBITDA Growth	0.00%	-144.69%	-90.39%	27.79%	32.12%	-134.19%	12.68%
EBIT Growth	0.00%	-142.87%	-89.44%	25.67%	35.44%	-139.43%	11.02%
NOPAT Growth	0.00%	-76.65%	-195.62%	13.76%	47.86%	-135.47%	7.67%
Net Income Growth	0.00%	-148.44%	-90.47%	22.00%	54.16%	-184.28%	78.77%
EPS Growth	0.00%	70.18%	-37.71%	28.42%	58.35%	-166.28%	82.31%
Operating Cash Flow Growth	0.00%	-32.97%	30.78%	133.99%	-762.29%	-132.75%	0.62%
Free Cash Flow Firm Growth	0.00%	0.00%	-650.28%	83.58%	-732.64%	-47.22%	0.16%
Invested Capital Growth	0.00%	-500.58%	-156.72%	-148.12%	39.49%	43.80%	96.47%
Revenue Q/Q Growth	0.00%	0.00%	6,538.16%	-33.75%	363.14%	-81.83%	150.88%
EBITDA Q/Q Growth	0.00%	-53.80%	8.09%	8.54%	51.06%	-112.68%	16.14%
EBIT Q/Q Growth	0.00%	-52.47%	7.66%	6.71%	49.89%	-121.29%	17.39%
NOPAT Q/Q Growth	0.00%	-12.19%	-6.13%	-8.15%	55.69%	-127.49%	17.71%
Net Income Q/Q Growth	0.00%	-53.25%	7.66%	8.36%	57.75%	-162.37%	80.71%
EPS Q/Q Growth	0.00%	39.36%	14.90%	5.28%	58.75%	-189.87%	81.72%
Operating Cash Flow Q/Q Growth	0.00%	-7.28%	28.28%	-75.92%	57.79%	-155.69%	-2.05%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-21.08%	-154.84%	38.53%	-66.23%	-8.09%
Invested Capital Q/Q Growth	0.00%	-2,417.92%	-33.40%	9.32%	11.83%	12.83%	96.16%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-433,172.22%	-794,958.33%	-700.67%	-430.58%	-47.14%	-656.46%	-266.59%
Operating Margin	-417,522.22%	-553,166.67%	-757.01%	-555.61%	-46.73%	-654.25%	-274.57%
EBIT Margin	-447,522.22%	-815,179.17%	-714.89%	-452.19%	-47.08%	-670.36%	-271.12%
Profit (Net Income) Margin	-435,144.44%	-810,800.00%	-714.91%	-474.54%	-35.09%	-593.13%	-57.24%
Tax Burden Percent	100.00%	100.00%	100.00%	111.11%	101.04%	100.01%	100.00%
Interest Burden Percent	97.23%	99.46%	100.00%	94.45%	73.75%	88.47%	21.11%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-389.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-360.04%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	311.86%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-77.59%	-112.32%	-69.13%	-37.06%	-15.46%	-43.94%	-8.11%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-51.60%	-64.38%	-38.48%	-19.56%	-12.70%	-33.22%	-29.31%
Return on Assets (ROA)	-50.18%	-64.03%	-38.49%	-20.53%	-9.46%	-29.39%	-6.19%
Return on Common Equity (ROCE)	154.58%	-14.41%	-69.13%	-37.06%	-15.46%	-43.94%	-8.11%
Return on Equity Simple (ROE_SIMPLE)	38.95%	-79.24%	-44.83%	-39.41%	-13.50%	-51.36%	0.00%
Net Operating Profit after Tax (NOPAT)	-53	-93	-275	-237	-124	-291	-269
NOPAT Margin	-292,265.56%	-387,216.67%	-529.91%	-388.93%	-32.71%	-457.98%	-192.20%
Net Nonoperating Expense Percent (NNEP)	-29.41%	-52.52%	-15.16%	-5.10%	-0.79%	-8.41%	18.02%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-32.30%	-12.59%	-39.66%	-21.64%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	114,183.33%	123,354.17%	110.37%	144.13%	30.93%	175.58%	81.45%
R&D to Revenue	303,438.89%	429,912.50%	746.64%	511.48%	115.80%	578.67%	293.12%
Operating Expenses to Revenue	417,622.22%	553,266.67%	857.01%	655.61%	146.73%	754.25%	374.57%
Earnings before Interest and Taxes (EBIT)	-81	-196	-371	-275	-178	-426	-379
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-78	-191	-363	-262	-178	-417	-373
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	19.27	6.57	3.76	2.26	2.80	2.27
Price to Tangible Book Value (P/TBV)	0.00	19.27	6.57	3.76	2.26	2.80	2.27
Price to Revenue (P/Rev)	10,000.00	197,180.98	104.73	45.24	5.87	32.33	20.13
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	29.21	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	21,922.89	184,694.69	86.11	27.54	2.72	18.94	11.24
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	74.48	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.04	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.04	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.87	-1.12	-1.18	-1.31	-1.32	-1.19	-1.06
Leverage Ratio	1.55	1.75	1.80	1.81	1.63	1.49	1.31
Compound Leverage Factor	1.50	1.74	1.80	1.70	1.20	1.32	0.28
Debt to Total Capital	4.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.22%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.22%
Long-Term Debt to Total Capital	4.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	286.69%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-190.88%	100.00%	100.00%	100.00%	100.00%	100.00%	99.78%
Debt to EBITDA	-0.06	0.00	0.00	0.00	0.00	0.00	-0.01
Net Debt to EBITDA	1.12	0.00	0.00	0.00	0.00	0.00	3.34
Long-Term Debt to EBITDA	-0.06	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.08	0.00	0.00	0.00	0.00	0.00	-0.01
Net Debt to NOPAT	1.66	0.00	0.00	0.00	0.00	0.00	4.63
Long-Term Debt to NOPAT	-0.08	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-1.06	11.66	4.37	1.76	2.32	0.88	5.60
Noncontrolling Interest Sharing Ratio	299.22%	87.17%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	3.24	3.01	5.96	4.89	5.89	4.82	13.09
Quick Ratio	3.15	2.93	4.52	4.82	5.79	4.67	12.85
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-25	-190	-31	-260	-382	-382
Operating Cash Flow to CapEx	-575.20%	-585.32%	-141.57%	46.02%	-442.30%	-3,881.58%	-2,308.99%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-21,102.94	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	-7,363.11	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-12,564.33	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.05	0.04	0.27	0.05	0.11
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.84	0.61	3.14	0.54	1.29
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	14	-54	-139	-345	-209	-117	-4.14
Invested Capital Turnover	0.00	0.00	-0.54	-0.25	-1.37	-0.39	-2.30
Increase / (Decrease) in Invested Capital	0.00	-68	-85	-206	136	91	113
Enterprise Value (EV)	395	4,433	4,464	1,678	1,029	1,203	1,570
Market Capitalization	180	4,732	5,430	2,756	2,219	2,054	2,813
Book Value per Share	($31.04)	$4.24	$12.13	$10.41	$12.04	$8.86	$12.20
Tangible Book Value per Share	($31.04)	$4.24	$12.13	$10.41	$12.04	$8.86	$12.20
Total Capital	105	246	827	733	981	734	1,241
Total Debt	4.41	0.00	0.00	0.00	0.00	0.00	2.71
Total Long-Term Debt	4.41	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-87	-300	-966	-1,078	-1,190	-851	-1,242
Capital Expenditures (CapEx)	13	16	47	49	34	8.95	15
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-26	-94	94	-209	-184	-155	-71
Debt-free Net Working Capital (DFNWC)	65	206	1,060	869	1,005	696	1,174
Net Working Capital (NWC)	65	206	1,060	869	1,005	696	1,172
Net Nonoperating Expense (NNE)	26	102	96	52	8.99	86	-189
Net Nonoperating Obligations (NNO)	-87	-300	-966	-1,078	-1,190	-851	-1,242
Total Depreciation and Amortization (D&A)	2.58	4.85	7.38	13	-0.21	8.83	6.34
Debt-free, Cash-free Net Working Capital to Revenue	-146,900.00%	-390,362.50%	181.17%	-342.80%	-48.82%	-243.49%	-50.62%
Debt-free Net Working Capital to Revenue	363,366.67%	858,266.67%	2,043.77%	1,426.96%	266.20%	1,095.88%	840.45%
Net Working Capital to Revenue	363,366.67%	858,266.67%	2,043.77%	1,426.96%	266.20%	1,095.88%	838.51%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($4.19)	($5.77)	($4.13)	($1.72)	($4.58)	($0.81)
Adjusted Weighted Average Basic Shares Outstanding	0.00	62.42M	64.23M	70.02M	77.15M	82.31M	98.91M
Adjusted Diluted Earnings per Share	$0.00	($4.19)	($5.77)	($4.13)	($1.72)	($4.58)	($0.81)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	62.42M	64.23M	70.02M	77.15M	82.31M	98.91M
Adjusted Basic & Diluted Earnings per Share	$0.00	($4.19)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	46.73M	68.73M	72.40M	81.66M	83.69M	101.86M
Normalized Net Operating Profit after Tax (NOPAT)	-53	-93	-275	-237	-124	-291	-269
Normalized NOPAT Margin	-292,265.56%	-387,216.67%	-529.91%	-388.93%	-32.71%	-457.98%	-192.20%
Pre Tax Income Margin	-435,144.44%	-810,800.00%	-714.91%	-427.08%	-34.73%	-593.07%	-57.24%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-41,181.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	-30,525.06	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	-46,382.22	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	-35,726.28	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-3.22%	-1.06%	-2.38%	-0.07%	-0.48%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Beam Therapeutics' official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	20.80%	8.82%	1,478.04%	-69.39%	-41.48%	-17.01%	-90.49%	0.81%	-28.08%	-32.03%	279.52%
EBITDA Growth	-36.74%	-29.04%	470.48%	-2.72%	-8.27%	2.28%	-165.04%	-5.16%	-7.69%	-12.29%	80.96%
EBIT Growth	-27.99%	-25.55%	393.81%	-3.85%	-11.06%	-0.01%	-176.67%	-7.77%	-8.92%	-13.66%	78.73%
NOPAT Growth	-24.62%	-18.58%	313.29%	-5.26%	-2.69%	1.63%	-152.71%	-14.55%	-14.54%	-19.07%	75.09%
Net Income Growth	-15.05%	12.31%	472.36%	-2.29%	-10.00%	-0.60%	-163.27%	-10.74%	-12.34%	-16.61%	370.38%
EPS Growth	-5.88%	21.79%	453.70%	9.02%	-2.78%	4.10%	-157.07%	-2.48%	9.91%	5.98%	332.11%
Operating Cash Flow Growth	-61.97%	-20.52%	295.22%	9.17%	1.96%	1.85%	-156.54%	-4.15%	7.90%	7.54%	-9.07%
Free Cash Flow Firm Growth	-182.89%	-203.45%	-102.27%	-15.15%	-2.64%	19.48%	-4,857.85%	11.62%	25.49%	34.65%	19.13%
Invested Capital Growth	28.58%	37.77%	39.49%	39.23%	41.05%	43.16%	43.80%	46.53%	32.81%	19.83%	96.47%
Revenue Q/Q Growth	-16.90%	-14.53%	1,739.07%	-97.66%	58.87%	21.21%	110.72%	-75.16%	13.33%	14.55%	1,076.62%
EBITDA Q/Q Growth	10.32%	-14.36%	225.24%	-185.82%	5.47%	-3.21%	16.64%	-29.31%	3.20%	-7.60%	84.36%
EBIT Q/Q Growth	10.99%	-14.84%	221.43%	-183.66%	4.81%	-3.42%	6.91%	-17.60%	3.79%	-7.89%	82.57%
NOPAT Q/Q Growth	-3.25%	-5.99%	275.30%	-154.86%	-0.73%	-1.53%	6.07%	-19.24%	-0.73%	-5.54%	80.35%
Net Income Q/Q Growth	14.19%	-16.08%	248.61%	-169.10%	7.72%	-6.17%	6.53%	-20.94%	6.39%	-10.20%	316.71%
EPS Q/Q Growth	18.80%	-12.96%	256.56%	-163.35%	8.26%	-5.41%	6.84%	-13.76%	19.35%	-10.00%	330.00%
Operating Cash Flow Q/Q Growth	22.90%	-6.04%	250.44%	-173.85%	16.78%	-6.16%	13.34%	-36.04%	26.41%	-6.58%	-2.22%
Free Cash Flow Firm Q/Q Growth	-6.84%	-24.57%	98.52%	-5,730.83%	4.78%	2.27%	8.63%	-3.95%	19.73%	14.27%	-13.06%
Invested Capital Q/Q Growth	12.28%	9.51%	11.83%	13.18%	14.91%	12.74%	12.83%	17.39%	-6.93%	-4.11%	96.16%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-484.62%	-648.42%	44.16%	-1,506.92%	-896.64%	-763.49%	-302.03%	-1,571.99%	-1,342.65%	-1,261.13%	-16.77%
Operating Margin	-507.79%	-629.72%	42.02%	-1,405.29%	-891.06%	-746.40%	-332.71%	-1,596.87%	-1,419.22%	-1,307.60%	-15.29%
EBIT Margin	-470.91%	-632.73%	41.78%	-1,491.47%	-893.66%	-762.46%	-336.85%	-1,594.47%	-1,353.52%	-1,274.81%	-18.88%
Profit (Net Income) Margin	-411.49%	-558.88%	45.16%	-1,331.57%	-773.45%	-677.47%	-300.51%	-1,462.78%	-1,208.26%	-1,162.38%	214.09%
Tax Burden Percent	100.00%	100.00%	299.35%	0.00%	100.04%	100.00%	47.80%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	87.38%	88.33%	36.11%	0.00%	86.51%	88.85%	186.63%	91.74%	89.27%	91.18%	-1,133.94%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-40.60%	-42.01%	-15.46%	-16.09%	-17.17%	-18.29%	-43.94%	-38.04%	-41.94%	-47.19%	-8.11%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-27.23%	-39.08%	11.27%	-399.90%	-240.96%	-216.57%	-16.69%	-71.73%	-61.51%	-57.21%	-2.04%
Return on Assets (ROA)	-23.80%	-34.52%	12.18%	-357.02%	-208.55%	-192.43%	-14.89%	-65.80%	-54.91%	-52.16%	23.15%
Return on Common Equity (ROCE)	-40.60%	-42.01%	-15.46%	-16.09%	-17.17%	-18.29%	-43.94%	-38.04%	-41.94%	-47.19%	-8.11%
Return on Equity Simple (ROE_SIMPLE)	-40.31%	-40.27%	0.00%	-14.75%	-16.74%	-18.15%	0.00%	-34.49%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-72	-76	133	-73	-73	-75	-70	-84	-84	-89	-17
NOPAT Margin	-355.46%	-440.80%	42.02%	-983.70%	-623.74%	-522.48%	-232.90%	-1,117.81%	-993.45%	-915.32%	-15.29%
Net Nonoperating Expense Percent (NNEP)	-1.01%	-1.92%	0.88%	-2.39%	-1.69%	-2.28%	-1.99%	-2.23%	-1.69%	-2.40%	25.01%
Return On Investment Capital (ROIC_SIMPLE)	-	-	13.54%	-	-	-	-9.55%	-7.43%	-8.03%	-9.18%	-1.41%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	122.57%	147.79%	13.68%	360.65%	251.67%	185.82%	95.32%	374.03%	317.26%	275.73%	28.29%
R&D to Revenue	485.23%	581.92%	44.30%	1,144.64%	739.39%	660.58%	337.39%	1,322.84%	1,201.96%	1,131.87%	87.00%
Operating Expenses to Revenue	607.79%	729.72%	57.98%	1,505.29%	991.06%	846.40%	432.71%	1,697.23%	1,519.55%	1,407.60%	115.24%
Earnings before Interest and Taxes (EBIT)	-95	-109	132	-111	-105	-109	-101	-119	-115	-124	-22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-97	-111	140	-112	-106	-109	-91	-117	-114	-122	-19
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.00	2.45	2.26	2.95	2.26	2.55	2.80	1.46	1.63	2.54	2.27
Price to Tangible Book Value (P/TBV)	3.00	2.45	2.26	2.95	2.26	2.55	2.80	1.46	1.63	2.54	2.27
Price to Revenue (P/Rev)	30.36	23.36	5.87	7.46	5.47	5.78	32.33	25.71	28.38	44.08	20.13
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	16.97	10.90	2.72	4.43	2.61	3.13	18.94	6.52	9.29	24.80	11.24
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.39	-1.41	-1.32	-1.29	-1.25	-1.24	-1.19	-1.14	-1.14	-1.14	-1.06
Leverage Ratio	1.72	1.77	1.63	1.61	1.57	1.57	1.49	1.39	1.40	1.41	1.31
Compound Leverage Factor	1.50	1.56	0.59	0.00	1.36	1.39	2.79	1.27	1.25	1.29	-14.87
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.12%	0.22%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.12%	0.22%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	99.88%	99.78%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.01
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.42	3.34
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.01
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.29	4.63
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	2.03	1.33	3.03	3.12	2.13	2.21	1.85	1.93	1.83	2.82	6.40
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.22	4.72	5.89	5.99	5.81	5.69	4.82	8.81	6.75	6.02	13.09
Quick Ratio	5.12	4.61	5.79	5.85	5.69	5.57	4.67	8.62	6.61	5.89	12.85
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-176	-219	-3.26	-190	-181	-177	-161	-168	-135	-115	-131
Operating Cash Flow to CapEx	-523.36%	-1,129.64%	3,763.53%	-4,091.35%	-4,232.99%	-5,588.14%	-2,571.21%	-3,389.36%	-2,437.82%	-1,626.00%	-2,230.56%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.06	0.06	0.27	0.27	0.27	0.28	0.05	0.05	0.05	0.04	0.11
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.68	0.68	3.14	2.97	2.87	2.90	0.54	0.55	0.53	0.50	1.29
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-261	-237	-209	-181	-154	-134	-117	-97	-104	-108	-4.14
Invested Capital Turnover	-0.26	-0.26	-1.37	-1.51	-1.70	-1.89	-0.39	-0.46	-0.47	-0.46	-2.30
Increase / (Decrease) in Invested Capital	105	144	136	117	107	102	91	84	51	27	113
Enterprise Value (EV)	1,361	889	1,029	1,598	920	1,093	1,203	414	560	1,381	1,570
Market Capitalization	2,434	1,905	2,219	2,693	1,929	2,019	2,054	1,634	1,710	2,455	2,813
Book Value per Share	$10.65	$9.84	$12.04	$11.18	$10.38	$9.60	$8.86	$13.42	$10.41	$9.55	$12.20
Tangible Book Value per Share	$10.65	$9.84	$12.04	$11.18	$10.38	$9.60	$8.86	$13.42	$10.41	$9.55	$12.20
Total Capital	812	779	981	913	854	791	734	1,123	1,047	967	1,241
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.19	2.71
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-1,073	-1,015	-1,190	-1,095	-1,008	-926	-851	-1,220	-1,150	-1,074	-1,242
Capital Expenditures (CapEx)	16	7.95	3.59	2.44	1.96	1.58	2.97	3.07	3.14	5.01	3.73
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-188	-196	-184	-160	-156	-146	-155	-114	-149	-158	-71
Debt-free Net Working Capital (DFNWC)	885	819	1,005	934	852	779	696	1,106	1,001	917	1,174
Net Working Capital (NWC)	885	819	1,005	934	852	779	696	1,106	1,001	916	1,172
Net Nonoperating Expense (NNE)	11	20	-9.94	26	18	22	20	26	18	24	-262
Net Nonoperating Obligations (NNO)	-1,073	-1,015	-1,190	-1,095	-1,008	-926	-851	-1,220	-1,150	-1,074	-1,242
Total Depreciation and Amortization (D&A)	-2.76	-2.70	7.53	-1.15	-0.35	-0.15	10	1.68	0.92	1.33	2.41
Debt-free, Cash-free Net Working Capital to Revenue	-234.22%	-240.68%	-48.82%	-44.35%	-44.26%	-41.89%	-243.49%	-179.12%	-247.22%	-283.28%	-50.62%
Debt-free Net Working Capital to Revenue	1,104.38%	1,004.46%	266.20%	258.93%	241.69%	222.88%	1,095.88%	1,739.70%	1,661.36%	1,646.61%	840.45%
Net Working Capital to Revenue	1,104.38%	1,004.46%	266.20%	258.93%	241.69%	222.88%	1,095.88%	1,739.70%	1,661.36%	1,644.47%	838.51%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.08)	($1.22)	$1.91	($1.21)	($1.11)	($1.17)	($1.09)	($1.24)	($1.00)	($1.10)	$2.53
Adjusted Weighted Average Basic Shares Outstanding	76.34M	79.02M	77.15M	81.70M	82.31M	82.41M	82.31M	87.98M	102.00M	102.57M	98.91M
Adjusted Diluted Earnings per Share	($1.08)	($1.22)	$1.91	($1.21)	($1.11)	($1.17)	($1.09)	($1.24)	($1.00)	($1.10)	$2.53
Adjusted Weighted Average Diluted Shares Outstanding	76.34M	79.02M	77.15M	81.70M	82.31M	82.41M	82.31M	87.98M	102.00M	102.57M	98.91M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	79.20M	81.50M	81.66M	82.31M	82.42M	82.81M	83.69M	100.56M	101.16M	101.47M	101.86M
Normalized Net Operating Profit after Tax (NOPAT)	-72	-76	93	-73	-73	-75	-70	-83	-84	-89	-12
Normalized NOPAT Margin	-355.46%	-440.80%	29.41%	-983.70%	-623.74%	-522.48%	-232.90%	-1,117.55%	-993.22%	-915.32%	-10.70%
Pre Tax Income Margin	-411.49%	-558.88%	15.09%	0.00%	-773.12%	-677.47%	-628.67%	-1,462.78%	-1,208.26%	-1,162.38%	214.09%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.10%	-0.22%	-0.48%	-0.42%	-0.27%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Beam Therapeutics (BEAM) has shown a mix of strong liquidity and ongoing operating losses in its recent quarterly reports. Here are the key trends across the last several years, focusing on cash flow, profitability, and balance sheet strength.

Beam ended Q4 2025 with about 1.07 billion dollars in liquidity (roughly 268 million in cash and 807 million in short-term investments), creating a solid runway for continued R&D and operations.
Gross margins appear very high in multiple quarters, with Total Cost of Revenue largely negligible or zero and Total Gross Profit tracking Revenue, indicating a strong margin backdrop on core activities.
Investing cash inflows were meaningful in recent quarters (Q4 2025 net cash from investing activities around +108 million; Q3 2025 around +65 million), reflecting favorable exits from investments.
The balance sheet shows a solid equity base and relatively low leverage, with Total Liabilities around 345 million and Total Equity near 966 million in 2025, suggesting a prudent capital structure for a biotech company.
Q4 2025 revenue spikes to 114.1 million, which appears to be driven by non-operating items and may not reflect ongoing core revenue growth.
R&D spending remains very high (roughly 90–110 million per quarter) along with substantial SG&A, sustaining a high operating expense base.
Net income in several quarters is influenced by non-operating gains/losses (for example, Q4 2025 shows a large net income from other income), making near-term profitability less indicative of core performance.
Operating cash flow is negative in every quarter shown (for example, Q4 2025 is about -83 million; Q3 2025 around -81.5 million; Q2 2025 around -76.5 million; Q1 2025 around -103.9 million), signaling ongoing cash burn from core activities.
GAAP net losses per share persist in most quarters (for instance, Q3 2025 EPS around -1.10; Q2 2025 around -1.11; Q1 2025 around -1.24), highlighting ongoing profitability challenges.
Significant equity issuance/dilution appears across periods (large common stock balances and multiple equity issuances), which could dilute existing shareholders.

05/05/26 05:30 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Beam Therapeutics' Financials

When does Beam Therapeutics' financial year end?

According to the most recent income statement we have on file, Beam Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Beam Therapeutics' net income changed over the last 6 years?

Beam Therapeutics' net income appears to be on an upward trend, with a most recent value of -$79.99 million in 2025, rising from -$78.33 million in 2019. The previous period was -$376.74 million in 2024. Check out Beam Therapeutics' forecast to explore projected trends and price targets.

What is Beam Therapeutics' operating income?

Beam Therapeutics' total operating income in 2025 was -$383.69 million, based on the following breakdown:

Total Gross Profit: $139.74 million
Total Operating Expenses: $523.44 million

How has Beam Therapeutics' revenue changed over the last 6 years?

Over the last 6 years, Beam Therapeutics' total revenue changed from $18 thousand in 2019 to $139.74 million in 2025, a change of 776,250.0%.

How much debt does Beam Therapeutics have?

Beam Therapeutics' total liabilities were at $242.82 million at the end of 2025, a 34.4% decrease from 2024, and a 340.3% increase since 2019.

How much cash does Beam Therapeutics have?

In the past 6 years, Beam Therapeutics' cash and equivalents has ranged from $37.22 million in 2019 to $559.99 million in 2021, and is currently $294.94 million as of their latest financial filing in 2025.

How has Beam Therapeutics' book value per share changed over the last 6 years?

Over the last 6 years, Beam Therapeutics' book value per share changed from -31.04 in 2019 to 12.20 in 2025, a change of -139.3%.

Related Companies

Financial statements for NASDAQ:BEAM last updated on 2/27/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Beam Therapeutics (BEAM) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Beam Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Beam Therapeutics (BEAM) Financials

Annual Income Statements for Beam Therapeutics

Quarterly Income Statements for Beam Therapeutics

Annual Cash Flow Statements for Beam Therapeutics

Quarterly Cash Flow Statements for Beam Therapeutics

Annual Balance Sheets for Beam Therapeutics

Quarterly Balance Sheets for Beam Therapeutics

Annual Metrics And Ratios for Beam Therapeutics

Quarterly Metrics And Ratios for Beam Therapeutics

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Beam Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools